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Abstract
Introduction: Statins, hydroxymethylglutaryl-coenzyme A reductase inhibitors, have been reported to have
antiinflammatory and/or immunomodulatory effects and prophylactic and therapeutic effects in collagen-induced
arthritis, an experimental model of rheumatoid arthritis (RA). The authors undertook to determine the effect of
atorvastatin on the expressions of osteoprotegerin (OPG) and receptor activator of nuclear factor B ligand (RANKL)
in RA fibroblast-like synoviocytes (FLSs), to identify the mechanisms responsible for these effects, and to determine
whether the statin inhibits osteoclastogenesis.
Methods: FLSs isolated from five RA patients were cultured in the presence of 20 ng/ml of tumor necrosis factor-a
(TNF-a) with or without atorvastatin. RANKL expressions were assayed with Western blotting and enzyme-linked
immunosorbent assay. RANKL, RANK, and OPG expression were assayed with reverse transcription-polymerase chain
reaction (RT-PCR). Osteoclast formation was assayed by counting cells after staining for tartrate-resistant acid
phosphatase in cocultures of peripheral blood mononuclear cells (PBMCs) and RA FLSs.
Results: Atorvastatin inhibited the expression of RANKL in RA FLSs in a dose-dependent manner, and the
suppression of RANKL was prevented by mevalonate. However, OPG expression was not affected by atorvastatin in
RA FLSs, and atorvastatin did not affect RANK expression in CD14+ cells. Conversely, atorvastatin suppressed TNF-a-
induced p38 phosphorylation in RA FLSs and significantly reduced TRAP-positive multinucleated osteoclast
formation in the coculture of PBMCs and RA FLSs.
Conclusion: These results suggest that atorvastatin inhibits osteoclastogenesis and bone destruction in RA
patients.
Introduction
Receptor activator of nuclear factor B ligand (RANKL),
and its receptor, RANK, have been found to be key factors
in the stimulation of osteoclast formation, and they have
also been suggested to play major roles in inflammation-
induced bone loss and joint destruction in arthritis [1,2].
The soluble tumor necrosis factor (TNF)-receptor mole-
cule, osteoprotegerin (OPG), is a natural inhibitor of
RANKL. OPG binds to RANKL and prevents it from
interacting with RANK, and thus, the balance between
RANKL and OPG in the bone microenvironment regu-
lates bone resorption [3].
Rheumatoid arthritis (RA) is characterized by inflam-
matory synovitis and progressive destruction of joint car-
tilage and bone [4,5]. Furthermore, RA patients exhibit
high serum levels of OPG and soluble RANKL [6];
RANKL mRNA is present in the synovial lining layer in
RA [7]. However, RANKL is not expressed in normal
synovium, which suggests a link between RANKL expres-
sion and the development of synovial lesions in RA [8].
In addition, recent studies provided genetic evidence that
RANKL and osteoclasts are central players in the inflam-
matory destruction of bone [9] and that enhanced
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RANKL expression in synoviocytes induced by synovial
inflammation may be critical for osteoclastogenesis [10].
Statins, hydroxymethylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors, constitute a family of chemi-
cally related molecules with lipid-lowering effects. Statins
are extensively used in medical practice, and large-scale
clinical trials have demonstrated their efficacies at redu-
cing cardiovascular-related morbidities and mortalities
[11,12]. Furthermore, increasing clinical and experimental
evidence indicates that statins might have general antiin-
flammatory and immunomodulatory effects; research
studies conducted over the last 10 years have elucidated a
number of mechanisms by which statins may exert antiin-
flammatory effects [13,14]. More recently, the beneficial
effects of statins have been extended to the direct immu-
nomodulation of monocyte-mediated inflammatory pro-
cesses (including chronic inflammatory diseases, such as
atherogenesis and RA), independent of their effects on
cholesterol levels [15-17].
Atorvastatin has been shown to have antiinflammatory
potential in RA clinical trials [18,19]. However, the
effects of atorvastatin on human osteoclasts have not
been determined. In this study, we examined the effects
of atorvastatin on the expressions of OPG and RANKL
in fibroblast-like synoviocytes (FLSs) from RA patients
and the mechanisms involved, and in addition, we




Atorvastatin (Pfizer, New York, NY, USA) was prepared
as a suspension in dimethyl sulfoxide (DMSO; Sigma,
St. Louis, MO, USA). Mevalonate (Sigma) was dissolved
in 1 N NaOH (pH 7.1). SB2035820, p38 inhibitor, was
purchased from Cell Signaling Technology (Danvers,
MA, USA).
Primary culture of FLS
Synovial tissues were obtained from five patients under-
going joint-replacement surgery. All five patients fulfilled
the 2010 rheumatoid arthritis classification criteria of RA
by the American College of Rheumatology/European
League Against Rheumatism collaborative initiative [20].
This study was approved by the Institutional Review
Board, and informed consent was obtained from
all patients. Their clinical characteristics are shown in
Table 1.
Synovial tissues were washed with phosphate-buffered
saline (PBS), minced, and digested for 2 hours at 37°C in
Dulbecco Modified Eagle’s Medium-High Glucose
(DMEM-HG; JBI, Daejeon, Korea) containing 1 mg/ml
type II collagenase (Worthington Biochemical Corpora-
tion, NJ, USA). The digested tissues were filtered through
a 70-μm cell strainer (Becton Dickinson, Franklin Lakes,
NJ, USA). Cell suspensions were centrifuged at 1,400
rpm for 20 minutes at room temperature, and cell pellets
were resuspended in DMEM-HG containing 1% penicil-
lin-streptomycin (Gibco/BRL, Grand Island, NY, USA)
and 10% heat-inactivated fetal bovine serum (FBS; Gibco/
BRL). The cells were then plated in 100-mm culture
dishes (Becton Dickinson) and incubated in a humidified
5% CO2 atmosphere. On reaching confluence, cells were
detached with 0.1% trypsin-EDTA (Gibco/BRL) and split
into 5 × 105 cells per dish. For all experiments, three- to
five-passage synovial fibroblasts were used.
Immunomagnetic selection of CD14+ cells
CD14+ cells were purified by MACS according to the
manufacturer’s instructions (Miltenyi Biotech, Auburn,
CA, USA). In brief, 107 PBMCs were resuspended in
80 μl of cold PBS containing 0.5% BSA and 2 mM EDTA
(MACS buffer). Microbeads (20 μl) conjugated with
mouse anti-human CD14IgG2a (Miltenyi Biotech) were
then added to cells and incubated for 15 minutes at 4°C.
Cells were then washed and resuspended in 3 ml of
MACS buffer and then applied to a preequilibrated sterile
LS separation column (Miltenyi Biotech) placed in a Mid-
iMACS magnet. The column was then washed 3 times
with MACS buffer, and CD14+ cells were eluted with
5 ml of MACS buffer after removing the column from
the magnet.
Methylthiazol tetrazolium assay
FLSs or PBMCs were cultured to confluence in 96-well
plates (Becton Dickinson) and treated with M-CSF
(2 ng/ml), 1,25-dihydroxyvitamin D3 (10
-7 M), atorvasta-
tin for 24 hours (10 to 100 μM) or 3 weeks (0.001 to
0.1 μM) in a 5% CO2 incubator. Methylthiazol tetrazo-
lium (MTT) labeling reagent (500 μg/ml; Sigma) was
added to FLSs or PBMCs in wells and incubated for
2 hours at 37°C. Isopropanol supplemented with 0.4 M
HCl was then added to release formazan dye from cells.
Formazan absorbance in solution was measured by
using a microtiter-plate enzyme-linked immunosorbent
assay (ELISA) reader at 570 nm.
Propidium iodide staining
FLSs were cultured in 100-mm culture dishes and treated
with TNF-a (20 ng/ml) and atorvastatin (10 to 100 μM)
for 24 hours. Cells were harvested by using 0.1% trypsin-
EDTA, washed twice in PBS containing 0.1% (wt/vol)
NaN3, and then 1 ml of cold 70% (vol/vol) ethanol was
added to cell pellets. Cells were then vortexed and incu-
bated at 4°C for 1 hour, washed twice, and resuspended
in 0.1 ml of PBS containing 0.1% NaN3. For DNA stain-
ing, cells were treated with 1 mg/ml of RNase A (Sigma),
resuspended in 0.5 ml of PBS containing 50 mg/ml
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propidium iodide (PI; Sigma), and incubated for 30 min-
utes at 4°C in the dark. They were then analyzed with
flow cytometry (FACS Caliber, BD Science), and the sub-
G0/G1 portion (the M1 fraction) was considered to be
the apoptotic fraction.
Reverse transcription-polymerase chain reaction and real-
time real-time PCR
Total RNA was extracted from FLSs or CD14+ cells by
using TRIzol reagent (Invitrogen Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. In brief, FLSs or CD14+ cells were cultured
in six-well plates in the presence or absence of TNF-a
(20 ng/ml), atorvastatin for FLSs (10 to 100 μM), for
CD14+ cells (0.01 to 1 μM) for 24 to 72 hours. The cells
were then lysed by adding 1 ml TRIzol reagent, and
lysates were collected in 1.5-ml microtubes, to which was
added 0.2 ml of chloroform (Sigma). The microtubes
were then centrifuged at 12,000 g for 15 minutes at 4°C,
and supernatants were transferred to new microtubes.
Isopropyl alcohol (0.5 ml) was then added to precipitate
RNA, and microtubes were centrifuged at 12,000 g for 8
minutes at 4°C. Pellets were washed with 75% ethanol,
dried at room temperature, and resuspended in 10 to
20 μl nuclease-free water (Applied Biosystems/Ambion,
Austin, TX, USA). RNA concentrations were determined
by measuring absorbance at 260 nm.
First-strand cDNA was synthesized by using a Power
cDNA Synthesis Kit (Intron Biotechnology, Seongnam,
South Korea). The reaction was conducted in 20 μl of buf-
fer containing 1 μg of total RNA, 0.2 mM oligo (dT)15 pri-
mer, 5× RT buffer, 40 mM DTT, 10 units of RNase
inhibitor, 2.5 mM deoxynucleotide triphosphate (dNTP)
mixture, and 5 units of AMV reverse transcriptase. After
incubation at 37°C for 1 hour, the reaction was stopped by
heating at 70°C for 15 minutes. To remove the remaining
RNA, 1 μl of Escherichia coli RNase H (4 mg/ml) was
added to reaction mixtures and this was followed by incu-
bation at 37°C for 30 minutes. The housekeeping gene,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was
used as an internal control for determining gene expres-
sion. The primers used to detect RANKL (S, 5’ GCC AGT
GGG AGA TGT TAG 3’; AS, 5’ TTA GCT GCA AGT
TTT CCC 3’); RANK (S, 5’ TTA AGC CAG TGC TTC
ACG GG 3’; AS, 5’ ACG TAG ACC ACG ATG ATG
TCG C 3’); OPG (S, 5’ TGC TGT TCC TAC AAA GTT
TAC C 3’; AS, 5’ CTT TGA GTG CTT TAG TGC GTG
3’), and GAPDH (S, 5’ GCT CTC CAG AAC ATC ATC
CC 3’; AS, 5’ CGT TGT CAT ACC AGG AAA TG 3’).
PCR amplification of cDNA was performed in an auto-
mated thermal cycler (GeneAmp PCR System 2400,
Applied Biosystems) in a final volume of 20 μl containing
1 to 4 μl of cDNA, 20 mM Tris-HCl (pH 8.4), 50 mM
KCl, 1.5 mM MgCl2, 0.1% Triton X-100, 0.2 mM dNTP
mixture, 0.5 pmol of each primer, and 5 units of Taq
DNA polymerase (Promega). After PCR, the amplified
products were analyzed with electrophoresis in 1.5%
agarose gel and visualized with ethidium bromide stain-
ing under UV illumination. Band intensities of PCR pro-
ducts were measured by using a UV/VIS Vilber Lourmat
digital camera and the software BioCaptMW (Vilber
Lourmat, Marne-la-Vallée, France).
Real-time PCR was performed with the ABI 7500 real-
time PCR system (Applied Biosystems). Total RNA was
extracted by using an RNeasy kit (Qiagen, Valencia, CA,
USA). Synthesis of cDNA was performed by using an
SuperScript III First-Strand Synthesis System (Invitrogen)
according to the manufacturer’s protocol. Quantitative
real-time PCR was performed by running a QuantiTect
SYBR Green PCR Kit (Qiagen). Primer sequences were as
follows; GAPDH, forward: CAATGACCCCTTCATT-
GACC; GAPDH, reverse: TGGACTCCACGACGTAC
TCA; and RANKL, forward GCTTGAAGCTCAGCCT
TTTG:; and RANKL, reverse: CGAAAGCAAATGTTGG-
CATA. The reactions were incubated at 94°C for 15 min-
utes for one cycle, and then at 94°C (15 seconds), 59°C (30
seconds), and 72°C (30 seconds) for 40 cycles. The quan-
tity of mRNA was calculated by using the threshold cycle
(Ct) value for amplification of human RANKL and for
human GAPDH as a reference gene. Relative gene expres-
sion was determined by the 2ΔΔCt method.
Western blot analysis
Protein expressions were measured with Western blotting.
In brief, cells were washed twice with ice-cold PBS,
scraped into microfuge tubes, pelleted by centrifugation,







1 180 Knee Female Prednisolone, 5 mg/d; celecoxib, 200 mg/d; gasmotine, 2.5 mg/d
2 36 Knee Female Cyclosporin A, 100 mg/d; triamcinolone, 2 mg/d
3 240 Knee Male Prednisolone, 5 mg/d; hydroxychloroquine, 200 mg/d; sulfasalazine, 500 mg/d
4 180 Hip Female Hydroxychloroquine, 200 mg/d
5 187 Knee Female Deflazacort, 5 mg/d; methotrexate, 12.5 mg/wk; leflunomide, 10 mg/d; hydroxychloroquine,
200 mg/d
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and suspended in PRO-PREP protein-extraction buffer
(Intron). After 30 minutes of incubation on ice, samples
were centrifuged at 14,000 rpm for 30 minutes at 4°C. Pro-
tein concentrations were measured by using Bio-Rad Pro-
tein Assay reagent (Bio-Rad) with bovine serum albumin
as a standard. Sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) was carried out by using a
mini-protein system (Bio-Rad). Dissolved protein samples
were combined with sample buffer (125 mM Tris (pH
6.8), 5% glycerol, 2% SDS, 1% 2-mercaptoethanol, and
0.006% bromophenol blue) boiled for 5 minutes, and
immediately cooled. Equivalent amounts of protein sam-
ples (50 μg/lane) were loaded onto 12% SDS gels. Electro-
phoresis was carried out in a running buffer at 100 V for
2 hours. Proteins were transferred from gels onto polyvi-
nylidene difluoride (PVDF) membranes (Millipore, Bed-
ford, MA, USA; 90 minutes at 30 V) in transfer buffer
(192 mM glycine, 25 mM Tris-HCl, pH 8.3, 0.02% SDS,
and 20% vol/vol TBS-Tween buffer (20 mM Tris, pH 8.0,
150 mM NaCl, and 0.1% Tween 20)) for 1 hour at 4°C.
After blocking with 5% nonfat dried milk in TBS-Tween
buffer for 1 hour, rabbit polyclonal antibody to human
RANKL (R&D), rabbit monoclonal anti-Akt/phospho-Akt,
anti-ERK/phospho-ERK, anti-JNK/phospho-JNK, anti-
p38/phospho-p38 antibodies (all from Cell Signaling Tech-
nology), and rabbit monoclonal anti-actin antibody
(Sigma) were added and incubated for 12 hours. Mem-
branes were then washed and incubated with HRP-conju-
gated goat anti-rabbit IgG polyclonal antibodies (1:1,000;
Jackson Immunoresearch, Philadelphia, PA, USA). Chemi-
luminescent substrate (Amersham Life Science, Arlington
Heights, IL, USA) was added, and incubation was contin-
ued for 10 minutes. Blots were then exposed to radio-
graphic film.
Enzyme-linked immunosorbent assay
The secretion of sRANKL was detected by using
RANKL ELISA kit (Peprotech), according to the manu-
facturer’s directions.
Coculture system for osteoclastogenesis
Blood was collected from healthy volunteers, and
PBMCs were isolated by centrifugation over Ficoll/
Paque at 1,700 rpm for 30 minutes. PBMCs were resus-
pended in a-MEM containing 10% FBS and 2 ng/ml
M-CSF (Sigma) and seeded at 2 × 105 cells/well in
96-well culture plates. On the following day, FLSs were
added at 2 × 104 cells/well to adherent PBMCs and
cocultured for 3 weeks in a-MEM containing 10% FBS,
100 IU/ml benzyl penicillin, 100 mg/ml streptomycin,
2 ng/ml M-CSF, and 10-7 M 1,25-dihydroxyvitamin D3.
The culture medium was replaced every 3 days. Adher-
ent cells were stained for tartrate-resistant acid phos-
phatase (TRAP) by using a commercially available kit
(Sigma), as previously described (10). TRAP-positive
multinucleated cells containing three or more nuclei
were identified as osteoclasts and counted with light
microscopy. All experiments were carried out 3 times in
triplicate.
Statistical analysis
Data are presented as mean ± SD. Statistical analysis
was performed by using SPSS version 12 (SPSS Inc.,
Chicago, IL, USA), and P values of < 0.05 were consid-
ered significant.
Results
Effects of atorvastatin on RANKL in the FLSs of RA
patients
FLSs were cultured for 24 hours with atorvastatin in the
presence of TNF-a (20 ng/ml), and assayed for RANKL
expression with RT-PCR and real-time PCR. Atorvastatin
significantly and dose-dependently inhibited the expres-
sion of RANKL mRNA in the FLSs of RA patients (P <
0.05) (Figure 1A, B). Western blotting of these cells
showed that atorvastatin also dose-dependently suppressed
RANKL protein levels (Figure 1C). Simvastatin has been
reported to reduce arthritis incidence, activity, and histolo-
gic scores in a collagen-induced arthritis model, and sim-
vastatin has been shown to have antiinflammatory
potential in RA patients (18,22). Therefore, we determined
whether simvastatin inhibits the expression of RANKL.
Simvastatin also significantly and dose-dependently
Figure 1 Effects of atorvastatin on receptor activator of
nuclear factor B ligand (RANKL) expression in fibroblast-like
synoviocytes (FLSs) from rheumatoid arthritis (RA) patients.
FLSs were isolated from three RA patients (patients numbers 1, 2,
and 3) and cultured in the presence of tumor necrosis factor
(TNF)-a (20 ng/ml) with or without atorvastatin for 24 hours. RANKL
expressions were analyzed with RT-PCR (A), real-time PCR (B), and
Western blotting (C). (D) TNF-a induced expression of RANKL
mRNA in the FLSs of RA patients. Total RNA was extracted from
FLSs cultured in the absence (-) or in the presence (+) of TNF-a
(20 ng/ml) for indicated times. Total RNA was analyzed with RT-PCR.
Results are representative of three independent experiments.
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inhibited the expression of RANKL mRNA and protein in
the FLSs of RA patients (see Additional file 1, Figure S1).
To determine the most effective time for TNF-a stimula-
tion, RANKL expression was analyzed with RT-PCR after
treating the FLSs of RA patients for 24 to 48 hours
with TNF-a (20 ng/ml). RANKL mRNA expression was
found to peak after 24 hours of stimulation with TNF-a
(20 ng/ml) (Figure 1D). Because mevalonate is synthesized
from 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) by HMG-CoA reductase, HMG-CoA reductase inhi-
bitors, like statins, reduce the entry of mevalonate into the
cholesterol synthesis pathway. To determine whether
mevalonate prevents the inhibition of RANKL expression
by atorvastatin, mevalonate (100 μM) was cotreated with
atorvastatin. RT-PCR and Western blotting showed that
mevalonate prevented the suppression of RANKL expres-
sion by atorvastatin (Figure 2). Also, mevalonate prevented
the inhibition of RANKL expression by simvastatin (see
Additional file 2, Figure S2).
The effects of atorvastatin on cell viability and apoptosis
The effect of atorvastatin on cell viability was deter-
mined by using an MTT-based assay (Figure 3A). Apop-
tosis was measured by staining with propidium iodide
(Figure 3B). Neither cell viability nor apoptosis was
affected by atorvastatin at concentrations of 10 to
100 μM. Simvastatin did not affect cell viability and
apoptosis (see Additional file 3, Figure S3).
Effects of atorvastatin on OPG in the FLSs of RA patients
The expressions of OPG mRNA were examined in FLSs
from patients cultured for 24 hours with RT-PCR.
Atorvastatin did not affect OPG expression in these
cells (Figure 4A). We also assayed the secretion of OPG
into the conditioned media of FLSs cultured in the pre-
sence of atorvastatin, and the statin was found to affect
OPG secretion (data not shown).
Effect of atorvastatin on RANK in CD14+ cells
The effect of atorvastatin on RANK in osteoclast precur-
sor cells was evaluated by purifying CD14+ cells from
total PBMCs by using a magnetic cell-separation
(MACS) system. Atorvastatin did not affect RANK
mRNA expression in CD14+ cells (Figure 4B), and the
viabilities of CD14+ cells were not affected by atorvasta-
tin at concentration up to 1 μM (Figure 4C).
Effect of atorvastatin on tumor necrosis factor-a-induced
signal-transduction pathways in FLSs from rheumatoid
arthritis patients
To investigate the mechanism by which atorvastatin
suppresses the expression of TNF-a-induced RANKL,
we examined its effects on the phosphorylations of p38
MAPK, JNK, ERK, and Akt. Western blotting revealed
that atorvastatin inhibited TNF-a-induced p38 phos-
phorylation after 12 hours, but that it did not affect the
phosphorylations of JNK, ERK, and Akt (Figure 5A).
When we pretreated cells with SB203580 (a p38 inhibi-
tor), TNF-a-induced RANKL mRNA expression was
decreased, which was similar to the suppression of
RANKL mRNA expression by atorvastatin (Figure 5B).
We also measured soluble RANKL levels in FLSs culture
media, and we found that its levels were decreased by
SB203580 and by atorvastatin (Figure 5C).
Inhibition of osteoclast formation
It was reported that RANKL is produced by RA FLS.
We added 1,25-dihydroxyvitamin D3 and M-CSF to
Figure 2 Effects of mevalonate on the statin-induced
suppression of RANKL. FLSs from RA patients (patients number 1
through 3) were cultured in the presence of TNF-a (20 ng/ml), and
then atorvastatin (50 to 100 μM) and mevalonate (100 μM) were
added for 24 hours. RANKL expressions were analyzed with RT-PCR
(A) and Western blotting (B). A representative experiment from
three independent experiments is shown.
Figure 3 The effects of atorvastatin on cell viability and
apoptosis. (A) Effects of atorvastatin on the viability of FLSs from
an RA patient (patients 1, 2, and 3). Cells were cultured for 24 hours
in the presence of TNF-a (20 ng/ml) and atorvastatin at different
concentrations (10 to 100 μM). Cell viabilities were determined by
using MTT assays. (B) Effects of atorvastatin on the apoptosis of
FLSs as determined by propidium iodide staining.
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media in which FLSs or cocultured cells were grown,
according to a previously described method [3]. We
could produce functionally active osteoclasts, and they
were determined by TRAP staining (Figure 6A). When
atorvastatin was added to cocultures of PBMCs and
FLSs for 3 weeks, atorvastatin at ≥0.01 μM significantly
decreased the numbers of TRAP-positive multinucleated
osteoclasts (P < 0.01 versus control) (Figure 6A, B). To
ensure that the inhibitory effect of atorvastatin on osteo-
clast formation was not due to an effect on cell viability,
we performed MTT assay. Cell viabilities were assayed
in separate cultures of FLSs and PBMCs. The viability of
PBMCs after 3 weeks of treatment in the presence of
M-CSF was not affected by atorvastatin (Figure 6C).
Furthermore, atorvastatin had no effect on FLS viability
after 3 weeks of treatment in the presence of vitamin D3
(Figure 6D).
Discussion
Statins inhibit the rate-limiting step of cholesterol synth-
esis by preventing HMG-CoA from being reduced to
mevalonate by HMG-CoA reductase [21]. In addition,
Figure 4 Effects of atorvastatin on osteoprotegerin (OPG)
expression in FLSs and RANK expression in CD14+ cells of RA
patients (patients 1, 4, and 5). (A) RT-PCR was used to analyze
OPG mRNA expression in FLSs cultured for 24 hours with 20 ng/ml
TNF-a and atorvastatin (10 to 100 μM). The results shown are
representative of three independent experiments. (B) CD14+ cells
were cultured for 48 or 72 hours in the presence of 2 ng/ml of
macrophage colony-stimulating factor and different concentrations
of atorvastatin (0.01 to 1 μM). RANK mRNA expression was not
affected by atorvastatin according to RT-PCR results. (C) Atorvastatin
had no effect on the viability of CD14+ cells at concentrations up to
1 μM. The results are representative of three independent
experiments.
Figure 5 The effect of atorvastatin on the phosphorylations of
ERK, JNK, Akt, and p38 MARK, induced by TNF-a in FLSs from
RA patients (patients 1, 4, and 5). (A) FLSs were cultured in the
presence of TNF-a (20 ng/ml) with or without atorvastatin (50 to 100
μM) for 24 hours to determine the effect of atorvastatin on the
activations of signaling molecules. Phosphorylated ERK, JNK, Akt, and
p38 MARK were analyzed by using Western blotting. Representative
Western blots from three independent experiments are shown. (B)
The effect of atorvastatin on the phosphorylation of p38 MARK
induced by TNF-a in FLSs from an RA patient. After serum
deprivation for 24 hours, FLSs were cultured with SB203580 (10 μM)
for 2 hours. TNF-a (20 ng/ml) and atorvastatin (50 to 100 μM) were
then added, and incubation was continued for another 24 hours. The
expressions of RANKL mRNA relative to GAPDH were determined
with RT-PCR. (C) RANKL secretion was determined with ELISA. Both
SB203580 and atorvastatin inhibited RANKL production by TNF-a.
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statins appear to have beneficial therapeutic effects on
several human diseases, such as multiple sclerosis (MS)
[22] and osteoporosis [23], which have no direct associa-
tion with cholesterol levels. Recently, a number of
reports have been issued on the antiinflammatory poten-
tials of statins in rheumatic disease [18,19,24,25] There-
fore, we hypothesized that atorvastatin could have
beneficial effects on the progressive joint destruction in
RA.
In a preliminary study, we confirmed that TNF-a
induced RANKL in FLSs from RA patients after incuba-
tion for 24 hours, which is consistent with that found by
Kubota et al. [26]. In the present study, we found that
atorvastatin inhibited the expression of TNF-a-induced
RANKL in FLSs from RA patients. Simvastatin also signifi-
cantly and dose-dependently inhibited the expression of
RANKL mRNA and protein in the FLSs of RA patients.
Mevalonate not only is a substrate for cholesterol bio-
synthesis, but also is required for the synthesis of several
other biologically important lipid intermediates by means
of an alternative synthesis pathway [27]. Furthermore, it is
well known that mevalonate prevents the effects of statins,
and in the present study, we found that the suppression of
RANKL expression by statins is prevented by mevalonate.
Osteoclasts play an important role in rheumatoid bone
erosion in RA [28-30], and RANKL plays an important
role in differentiation of osteoclasts from their precursor
cells and promotes the activity and survival of these cells,
which leads to bone resorption [31]. In the present study,
the results were obtained by using a coculture system for
osteoclastogenesis and showed that atorvastatin inhibits
osteoclast formation. To our knowledge, this is the first
report describing that atorvastatin inhibits osteoclastogen-
esis by attenuating RANKL expression in the FLSs of RA.
Figure 6 Effect of atorvastatin on osteoclast formation. (A) Osteoclast formation was assayed with tartrate-resistant acid phosphatase (TRAP)
staining and counting positive cells containing three or more nuclei under a light microscope (original magnification, ×100). (B) Peripheral blood
mononuclear cells (PBMCs; 2 × 105 cells/well) from a healthy donor were cocultured with fibroblast-like synoviocytes from a rheumatoid arthritis
patient (RA FLSs; 2 × 104 cells/well, patients 1, 4, and 5) in the presence of macrophage colony-stimulating factor, 1,25-dihydroxyvitamin D3, and
different concentrations (0.001 to 0.1 μM) of atorvastatin in 96-well plates for 3 weeks. Cell viabilities were assayed in separate cultures of FLSs and
PBMCs. (C) PBMCs were cultured for 3 weeks in the presence of 10-7 M 1,25-dihydroxyvitamin D3 and different concentrations of atorvastatin. (D)
RA FLSs were cultured for 3 weeks in the presence of 2 ng/ml macrophage colony-stimulating factor and different concentrations of atorvastatin
(0.001 to 0.1 μM). Bars represent means and SDs. All experiments were carried out 3 times in triplicate. *P < 0.01 versus control.
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In the present study, we performed cocultures at
lower atorvastatin concentrations (0.001 to 0.1 μM).
Exposure to higher concentrations (1 μM or more) for 3
weeks was found to be toxic to both FLSs and PBMCs
(data not shown).
The receptor activator of the NF-B (RANK)/RANKL
system has been shown to be a critical factor during
osteoclast differentiation and bone resorption [31-33]. In
addition, osteoprotegerin (OPG) functions as a high-affi-
nity soluble decoy receptor for RANKL and competes
with RANK for RANKL binding. Therefore, OPG is an
effective inhibitor of the RANK-RANKL interaction.
Several research groups have assessed the role of the
RANK/RANKL/OPG system in RA, and experimental
arthritis models have been established to study the in
vivo effects of these molecules [4]. Recently, RANKL
was reported to participate in osteoclast formation in a
model of spontaneously developing erosive arthritis in
the mouse [30]. However, in the present study, atorvas-
tatin did not enhance the expressions of OPG protein
and mRNA, and atorvastatin did not affect RANK
expression in CD14+ cells. These findings indicate that
the inhibition of osteoclast formation by atorvastatin is
independent of OPG and RANK.
Signaling pathways that regulate proinflammatory
mediator expression in FLSs of RA patients include
MAPKs and NF-B. Three MAPK families have been
implicated in RA: ERK1/2, JNK, and p38 MAPK [34].
Interestingly, all three of these MAPK families are acti-
vated in RA synovial tissue and in cultured FLSs from
RA patients. Furthermore, TNF-a has the potential to
signal through all three [35]. However, we observed that
atorvastatin decreased the phosphorylation of p38 but
not that of ERK 1/2 or JNK, and that SB203580 (a speci-
fic p38 inhibitor) had a similar inhibitory effect on
RANKL production in the FLSs of RA patients. There-
fore, p38 may play a central role in which atorvastatin
suppresses the expression of RANKL by TNF-a.
Conclusions
The present study shows that atorvastatin markedly
reduce RANKL expression in the fibroblast-like synovio-
cytes of rheumatoid arthritis patients, and atorvastatin
inhibits osteoclastogenesis in co-cultures of PBMCs and
FLSs. These results suggest that atorvastatin may inhibit
osteoclastogenesis and bone destruction in RA patients.
Additional material
Additional file 1: Figure S1. Effects of simvastatin on receptor
activator of nuclear factor B ligand (RANKL) expression in
fibroblast-like synoviocytes (FLSs) from rheumatoid arthritis (RA)
patients (patients 1, 2, and 3). FLSs were isolated from three RA
patients and cultured in the presence of TNF-a (20 ng/ml) with or
without simvastatin (10 to 100 μM) for 24 hours. RANKL expressions were
analyzed with RT-PCR (A) and Western blotting (B).
Additional file 2: Figure S2. Effects of mevalonate on the statin-
induced suppression of RANKL. FLSs from RA patients (patients 1, 2,
and 3) were cultured in the presence of TNF-a (20 ng/ml), and then
simvastatin (50 to 100 μM) and mevalonate (100 μM) were added for 24
hours. RANKL expressions were analyzed with RT-PCR (A) and Western
blotting (B).
Additional file 3: Figure S3. The effects of simvastatin on cell
viability and apoptosis. (A) Effects of simvastatin on the viability of
FLSs from an RA patient (patients 1, 2, and 3). Cells were cultured for 24
hours in the presence of TNF-a (20 ng/ml) and simvastatin at different
concentrations (10 to 100 μM). Cell viabilities were determined by using
MTT assays. (B) Effects of simvastatin on the apoptosis of FLSs, as
determined by propidium iodide staining.
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immunosorbent assay; FLS: fibroblast-like synoviocyte; GAPDH:
glyceraldehyde 3-phosphate dehydrogenase; HMG-CoA:
hydroxymethylglutaryl-coenzyme A; MAPK: mitogen-activated protein kinase;
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